Cite
HARVARD Citation
Krogstad, P. et al. (2021). Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. Journal of the Pediatric Infectious Diseases Society. pp. 201-204. [Online].